Smith & Nephew plc SNN
At closeNov 6, 2026, 4:25 PM EST
After hours · Nov 6, 4:25 PM ET
- YTD
- -5.06%
- 1 year
- -4.01%
- Market cap
- 13.04B
- Revenue (ttm)
- 6.30B
- Profit margin
- 10.08%
- EPS (ttm)
- 1.47
- Shares out
- 418.52M
- P/E ratio
- 21.19
- Forward P/E
- 13.15
- Dividend
- 0.79 (2.48%)
- Ex-dividend date
- Oct 1, 2026
- YTD return
- -5.06%
- 1-year return
- -4.01%
- Volume
- 1.86M
- Avg volume
- 1.49M
- Open
- 30.73
- Previous close
- 32.01
- Day's range
- 30.68 – 31.27
- 52-week range
- 26.12 – 37.09
- Beta
- 0.67
- Analysts
- Hold
- Price target
- 32.72 (+5.0%)
- Earnings date
- Mar 1, 2027
5D +1.49 (+5.02%)
Key statistics
- Enterprise value
- 71.14B
- PEG ratio
- 1.24
- Price / sales
- 2.07
- Price / book
- 12.80
- Dividend yield
- 2.48%
- Payout ratio
- 53.20%
- Revenue growth
- 4.60%
- Free cash flow
- 1.06B
- Total cash
- 754.00M
- Total debt
- 3.78B
- Return on equity
- 11.85%
- Short % of float
- 0.97%
- 50-day average
- 28.46
- 200-day average
- 31.04
Analyst view
Consensus: hold
- Target (low)
- 30.00
- Target (mean)
- 32.72
- Target (high)
- 38.00
- Strong buy1
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 0.53.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 27, 2026 | 1.18 | — | — | — |
| Aug 4, 2026 | Jun 27, 2026 | 0.939 | 0.946 | +0.01 | +0.75% |
| Mar 2, 2026 | Dec 31, 2025 | 1.16 | 1.18 | +0.02 | +1.72% |
| Aug 5, 2025 | Jun 30, 2025 | 0.79 | 0.858 | +0.07 | +8.61% |
| Feb 25, 2025 | Dec 31, 2024 | 0.92 | 0.938 | +0.02 | +1.96% |
| Oct 31, 2024 | Jun 29, 2024 | 0.80 | 0.50 | -0.30 | -37.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2026 | BTIG | init | — | Neutral |
| Aug 6, 2026 | JP Morgan | down | Overweight | Neutral |
| Aug 5, 2026 | Barclays | down | Equal-Weight | Underweight |
| May 11, 2026 | Canaccord Genuity | main | Hold | Hold |
| Mar 5, 2026 | Canaccord Genuity | main | Hold | Hold |
| Nov 11, 2025 | Canaccord Genuity | main | Hold | Hold |
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United Kingdom
- Website
- smith-nephew.com
News
Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript Smith+Nephew Q3 Revenue Rises 3.4% YoY To $1.551B; $250M Of $500M Buyback Completed; Confirms Johnson & Johnson Talks Ended, Still Exploring Orthopaedics Strategic Options
Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session CORRECTION: Smith & Nephew Lowers FY2026 Sales Guidance from $6.534B to $6.411B vs $6.565B Est
Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo Classification
Canaccord Genuity Maintains Hold on Smith & Nephew, Lowers Price Target to $30
Smith+Nephew To Showcase ALLEVYNCOMPLETE CARE Dressing And RENASYS EDGE tNPWT, To Simplify Wound Management And Ease Clinical Burden At EWMA 2026
Your note
Sign in to keep a note on SNN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bank Of America Securities Llc | — | Holding | Jul 19, 2026 | 10,038,466 |
| BlackRock Investment Management (UK) Ltd. | — | Decrease | Nov 13, 2025 | 433,611 |
| Connolly (Paul) | — | Bought | Jul 9, 2026 | 2,833 |
| Dhankhar (Ajay) | — | Bought | Nov 5, 2025 | 18,460 |
| King (David) | — | Bought | Aug 18, 2025 | 2,800 |
| Kong (Garheng) | — | Bought | Nov 5, 2025 | 3,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| River Road Asset Management, LLC | 0.77% | 3,221,876 | 100.38M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 0.73% | 3,069,598 | 95.63M | Jun 29, 2026 |
| Brandes Investment Partners L.P. | 0.51% | 2,148,731 | 66.94M | Jun 29, 2026 |
| LMR Partners LLP | 0.42% | 1,767,872 | 55.08M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 0.42% | 1,766,140 | 55.02M | Sep 29, 2026 |
| Causeway Capital Management LLC | 0.37% | 1,565,167 | 48.76M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.08% | 333,428 | 10.39M | Sep 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.07% | 273,638 | 8.53M | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional International Core Equity 2 ETF | 0.07% | 297,661 | 9.27M | Jul 30, 2026 |
| American Century ETF Trust-Avantis International Equity ETF | 0.07% | 272,420 | 8.49M | Sep 29, 2026 |
| 2023 ETF Series Trust-Brandes International ETF | 0.06% | 256,404 | 7.99M | Jun 29, 2026 |
| JNL Series Trust-JNL MULTI-MANAGER SMALL CAP VALUE FUND | 0.05% | 201,147 | 6.27M | Jun 29, 2026 |
